GlassScriptPhysician profile
Megan Kral
NPI 1538673538
$2,475.50
in general payments reported to CMS, 2019-2025
26 companies · $509 in 2025
The $509 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $584 · 2022: $285 · 2023: $607 · 2024: $491 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $836.22 | 2023-2025 | Qutenza |
| Amgen INC. | $254.99 | 2021-2024 | Evenity, Prolia, Tezspire |
| Baxter Healthcare | $159.83 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Lilly USA, LLC | $148.06 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $144.85 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Tersera Therapeutics LLC | $136.80 | 2023-2024 | Prialt |
| Abbvie INC. | $128.08 | 2021-2022 | |
| Abbott Laboratories | $74.18 | 2022 | |
| Grt US Holding, INC. | $70.95 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $70.01 | 2021-2025 | Acthar |
| United Therapeutics Corporation | $63.36 | 2021-2025 | Tyvaso, Tyvaso |
| Teva Pharmaceuticals USA, INC. | $52.42 | 2021 | |
| Biodelivery Sciences International, INC. | $51.09 | 2021 | |
| Collegium Pharmaceutical, INC. | $47.72 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $34.96 | 2022-2025 | Opsumit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $26.22 | 2023 | Yupelri |
| Mml US, INC. | $25.56 | 2025 | Reactiv8 |
| Relievant Medsystems, INC. | $23.89 | 2021 | |
| Pfizer INC. | $20.40 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $20.00 | 2025 | Dupixent |
| Ani Pharmaceuticals, INC. | $19.94 | 2025 | Purified Cortrophin Gel |
| Hikma Pharmaceuticals USA | $16.53 | 2022 | |
| Viatris Specialty LLC | $13.50 | 2025 | Yupelri |
| Advanced Respiratory, INC | $12.69 | 2021 | |
| Almatica Pharma LLC | $12.08 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Kral listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.